Search

Edwards Lifesciences Corp

Slēgts

SektorsVeselības aprūpe

85.64 2.51

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

82.71

Max

85.47

Galvenie mērījumi

By Trading Economics

Ienākumi

290M

381M

Pārdošana

92M

1.7B

P/E

Sektora vidējais

49.429

64.641

EPS

0.78

Peļņas marža

23.092

Darbinieki

16,000

EBITDA

20M

520M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+22.94% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.1B

48B

Iepriekšējā atvēršanas cena

83.13

Iepriekšējā slēgšanas cena

85.64

Ziņu noskaņojums

By Acuity

55%

45%

253 / 340 Rangs Healthcare

Edwards Lifesciences Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. jūl. 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

2026. g. 27. jūl. 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

2026. g. 24. jūl. 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

2026. g. 23. jūl. 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

2026. g. 22. jūl. 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

2026. g. 21. jūl. 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

2026. g. 20. jūl. 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Salīdzinājums

Cenas izmaiņa

Edwards Lifesciences Corp Prognoze

Cenas mērķis

By TipRanks

22.94% augšup

Prognoze 12 mēnešiem

Vidējais 102.88 USD  22.94%

Augstākais 110 USD

Zemākais 85 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Edwards Lifesciences Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

19 ratings

16

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

253 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat